Precision Medicine in Type 2 Diabetes & Cardiovascular disease 31 August–1 September 2016 at Hotel Skansen in Båstad, Sweden

Uppgifter
Kategori: Nyheter

Dear colleagues, 

This is an invitation to a meeting in southern Sweden this summer Aug 31st and Sept 1st on precision medicine in type 2 diabetes and CVD http://www.sls.se/precisionmedicine
 
Nyhetsinfo
www red DiabetiologNytt
 
We have put together an outstanding programme, which I believe will be of high interest to you. This will be a 2-day, single-track meeting of around 200 speakers and delegates and promises to be a great platform for discussion and future collaboration.
 
Please consider signing-up and encouraging your colleagues and fellows to do the same. 
 
With best wishes,
 
Paul Franks and Peter M Nilsson
 
Paul W. Franks PhD (Cantab) MPhil (Cantab) MS FTOS | Professor & Head of Unit
Genetic & Molecular Epidemiology Unit, Lund University Diabetes Centre, Malmö, Sweden 
Professor (adjunct) - Harvard School of Public Health, Boston, MA
 
www.ludc.med.lu.se/game
www.hsph.harvard.edu/faculty/paul-franks/
 
Berzelius symposium 91
Precision Medicine in Type 2 Diabetes & Cardiovascular disease
31 August–1 September 2016 at Hotel Skansen in Båstad, Sweden
 
More information and registration: http://www.sls.se/precisionmedicine/
 

Wednesday, August 30th
Registration for delegates start at 4 pm.

Wednesday, August 31st
 
09.00-09.15 Welcome and introduction. 
Paul Franks, Lund University Diabetes Center, Sweden
 
09.15-10.00 Precision medicine: where are we and where are we going? 
Leif Groop, Lund University Diabetes Center, Sweden

10.00-10.45 What industry wants from academic partnerships in precision medicine. 
Hartmut Ruetten, Sanofi, Germany
 
10.45-11.15 Coffee break  (poster session 1)
 
11.15-12.15 Why national initiatives and global collaborations are needed and how they are taking shape. Phil Smith, NIDDK, US
 
12.15-13.30 Lunch
 
13.30-14.15 The genetics of therapeutic response. Jose Florez, Harvard, US
 
14.15-15.00 Is genotype-guided lifestyle therapy on the horizon? 
Anna Krook, Karolinska Institutet, Sweden
 
15.00-15.30 Coffee break  (poster session 2)
 
15.30-16.15 Societal and ethical implications of genetically-guided medicine. 
Andy Miah, Salford, UK
 
16.15-17.00 Functional genomics. Manolis Kellis, MIT, US

17.00-17.45 Elucidating mechanisms. Anna Gloyn, Oxford, UK

19.00-22.00 Symposium dinner
 
 
Thursday, September 1st
 
09.00-09.45 What can monogenic obesity teach us about disease stratification and personalized treatment in type 2 diabetes? Giles Yeo, Cambridge, UK
 
09.45-10.30 What can monogenic diabetes teach us about disease stratification and personalized treatment in type 2 diabetes? Andrew Hattersley, Exeter, UK
 
10.30-11.15 Making precision medicine personal. Mike Snyder, Stanford, US
 
11.15-12.00 Commercialization of precision medicine. Adam Auton, 23andMe, US

12.00-13.00 Lunch
 
13.00-14.00 Debate: precision medicine will transform patient care for the better:
for: Ewan Pearson, University of Dundee, UK
against: Simon Griffin, University of Cambridge, UK
 
14.00-14.45 Nature genetics' view of the prospects for precision medicine. 
Myles Axton, Cheif Editor, Nature Genetics
 
14.45-15.00 Coffee break (poster session 3)
 
15.00-15.45 Innovation in big data analysis. Mark McCarthy, Oxford, UK
 
15.45-16.00 Closing remarks. Paul Franks

Träffar: 2974